The November update to the AHFS Drug Information/Essentials database has been published. Highlights from this month’s update include:

New AHFS/Essentials Monographs

• Alectinib (Alecensa^®)
• Atezolizumab (Tecentriq^®)
• Daratumumab (Darzalex^®)
• Elotuzumab (Empliciti^®)
• Ixazomib (Ninlaro^®)
• Necitumumab (Portrazza^®)
• Osimertinib (Tagrisso^®)
• Palbociclib (Ibrance^®)
• Sonidegib (Odomzo^®)
• Trabectedin (Yondelis^®)
• Trifluridine and Tipiracil (Lonsurf^®)
• Venetoclax (Venclexta^®)

FDA MedWatch Alerts

• FDA is warning about the risk of hepatitis B virus (HBV) reactivation in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral medicines for hepatitis C virus.
  • Affected monographs:
    • Simeprevir
    • Sofosbuvir
    • Ledipasvir and Sofosbuvir
    • Ombitasvir, Paritaprevir, and Ritonavir with Dasabuvir Sodium
    • Daclatasvir
    • Ombitasvir/Paritaprevir/Ritonavir
    • Elbasvir and Grazoprevir
• FDA added a new warning and updating the Abuse and Dependence section to include new safety information regarding the risks associated with abuse and dependence of testosterone and other anabolic steroids.
  • Affected monographs:
    • Oxandrolone
    • Danazol
    • Testosterone
    • Methyltestosterone
    • Fluoxymesterone